MiR-375, which is also down-regulated in HCC, inhibits AKT activation by targeting AEG-1, suppresses tumor angiogenesis in HCC, and reverses the sorafenib resistance of HCC (31). The gene discussed is AKT1; the disease is hepatocellular carcinoma.